Pioglitazone may reduce body fat inflammation in insulin resistance
Last updated May 6, 2026
Key finding
In insulin-resistant adults with impaired glucose tolerance, pioglitazone was linked to fewer inflammatory cells in adipose tissue, better capillary density, higher elastin content, and improved insulin sensitivity.
This study re-examined fat tissue from insulin-resistant adults before and after pioglitazone treatment. Pioglitazone was linked to fewer adipose macrophages and mast cells, more capillaries, higher elastin content, and better insulin sensitivity. Because the treatment group was small and the analysis was based on secondary tissue studies, the findings are promising but not definitive.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Low
Study type
non-randomized clinical trial (non-RCT or NRCT)
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
In insulin-resistant adults with impaired glucose tolerance, pioglitazone was linked to fewer inflammatory cells in adipose tissue, better capillary density, higher elastin content, and improved insulin sensitivity.
Published in
Journal Reference
Publication details and source links for this paper.
Spencer M, Yang L, Adu A, et al. Pioglitazone Treatment Reduces Adipose Tissue Inflammation through Reduction of Mast Cell and Macrophage Number and by Improving Vascularity. PLoS One. 2014;9(7):e102190. doi:10.1371/journal.pone.0102190
Main Effects
Adipose tissue macrophage count ↓ after pioglitazone
Adipose tissue mast cell count ↓ after pioglitazone
Capillary density ↑ and elastin content ↑ in adipose tissue
Insulin sensitivity ↑ after treatment
Evidence Suggest
- Pioglitazone lowered total adipose macrophages and reduced pro-inflammatory M1 macrophages.
- Mast cell density fell from 24 to 13 cells per mm2 after pioglitazone treatment.
- Capillary density and adipose elastin content increased, suggesting improved tissue structure and blood supply.
- Insulin sensitivity improved in the treated participants in the paired pre-post analysis.
Who this applies to
These findings apply most directly to obese, insulin-resistant adults with impaired glucose tolerance who are at high risk for type 2 diabetes. The results are especially relevant to people being studied for early metabolic dysfunction rather than established treated diabetes.
Keep in Mind
The improvements were seen mainly in adipose tissue biology and insulin sensitivity, not in a large clinical outcomes trial. The treatment group was small, and this paper re-used participants from previous intervention studies. That means the study helps explain how pioglitazone may work, but it does not by itself prove broad clinical benefit for all high-risk patients.
Between the Lines
- Only nine participants were included in the pioglitazone tissue analysis.
- This was a secondary mechanistic analysis based on prior intervention cohorts.
- There was no dedicated parallel placebo group for the pioglitazone biopsy analysis.
- Most outcomes were tissue and biomarker measures rather than patient-centered clinical outcomes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.